Skip to main content

Bayer Aktiengesellschaft's Form 4 filing

Senti Biosciences Holdings, Inc. (SNTI) · filed Dec 11, 2024

Accession no.
0001578563-24-000493
Filed
Dec 11, 2024, 7:38 PM ET
Trade date
Dec 9, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 derivative transactions. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bayer AktiengesellschaftCIK 000114414510% Owner
Bayer Healthcare LLCCIK 000123151710% Owner
Bayer World Investments B.V.CIK 000182002710% Owner
Bayer US Holding LPCIK 000196575410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 9, 2024Common StockPPurchaseAcquired+2,222,000–F3–2,222Direct
Dec 9, 2024Common StockPPurchaseAcquired+3,333,000–F3–3,330,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased.

Referenced by the price of 2 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)